VCA Stocks

Santaris Pharma A/S has announced that it has completed a EUR 40m ($58.8mm) private investment round.  The proceeds of the financing will be used primarily to fund continued development of Santaris Pharma’s portfolio of innovative drug candidates based on LNA (Our unique RNA Antagonist, based on the RNA analogue, Locked Nucleic Acid), including SPC2996, an RNA Antagonist to Bcl-2, currently in an international Phase I/II clinical trial in patients with the blood cancer, chronic lymphocytic leukaemia. The funds will enable the start of clinical studies with other RNA Antagonists and the further development of Santaris Pharma’s world-leading platform for LNA-based human therapeutics.